JAC Advance Access published online on March 31, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh184
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 The JONES Group/JMI Laboratories,
345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317; Tufts University School of Medicine,
Boston, MA, USA
* Corresponding author. E-mail: ronald-jones{at}jmilabs.com.
Received 15 December 2003
; revised 8 February 2004
; accepted 13 February 2004
Objectives: To evaluate the potency
of a novel peptide deformylase inhibitor, NVP PDF-713, against
Gram-positive organisms having resistances to linezolid
or quinupristin/dalfopristin. Materials and methods: A total of 45 strains
from three genera (six species groups) were tested by reference broth
microdilution methods. The mechanism of resistance to the oxazolidinone
was determined by sequencing of the gene encoding the ribosomal
target. Results: NVP PDF-713 retained activity against
linezolid-resistant staphylococci (MIC range 0.25-2 mg/L), Streptococcus oralis (MIC 0.5 mg/L), Enterococcus
faecalis (MIC range 2-4 mg/L) and Enterococcus faecium (MIC
range 0.5-4 mg/L). Quinupristin/dalfopristin-resistant E. faecium (MIC range 1-2 mg/L)
and staphylococci (MIC range 0.12-2 mg/L) were also
inhibited by NVP PDF-713. Many (10 of 13 strains) of the linezolid-resistant
enterococci were resistant to vancomycin and these clinical strains
had a G2576U ribosomal target mutation. Conclusions: NVP PDF-713 appears to be a promising
clinical candidate among the peptide deformylase inhibitors for
the treatment of infections caused by Gram-positive organisms that
possess resistances to oxazolidinones or streptogramin combinations.
Keywords: streptococci, enterococci, staphylococci, streptogramins,
oxazolidinones
Potential utility of a peptide deformylase inhibitor
(NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant
Gram-positive organism isolates
2 The JONES Group/JMI Laboratories,
345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317;
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. S. Osborne, G. Neckermann, E. Fischer, R. Pecanka, D. Yu, K. Manni, J. Goldovitz, K. Amaral, J. Dzink-Fox, and N. S. Ryder In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3777 - 3781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sreenivas, P. V. S. Amarnath, A. Mallik, H. Sarnaik, N. S. Kumar, M. Takhi, S. Trehan, M. S. Kumar, J. Iqbal, R. Rajagopalan, et al. In vitro and in vivo antibacterial evaluation of DRF 8417, a new oxazolidinone J. Antimicrob. Chemother., July 1, 2007; 60(1): 159 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosowska-Shick, K. L. Credito, G. A. Pankuch, B. DeWasse, P. McGhee, and P. C. Appelbaum Multistep Resistance Selection and Postantibiotic-Effect Studies of the Antipneumococcal Activity of LBM415 Compared to Other Agents Antimicrob. Agents Chemother., February 1, 2007; 51(2): 770 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bogdanovich, K. A. Smith, C. Clark, G. A. Pankuch, G. Lin, P. McGhee, B. Dewasse, and P. C. Appelbaum Activity of LBM415 Compared to Those of 11 Other Agents against Haemophilus Species. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2323 - 2329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Balakrishnan, B. Patel, S. A. Sieber, D. Chen, N. Pachikara, G. Zhong, B. F. Cravatt, and H. Fan Metalloprotease Inhibitors GM6001 and TAPI-0 Inhibit the Obligate Intracellular Human Pathogen Chlamydia trachomatis by Targeting Peptide Deformylase of the Bacterium J. Biol. Chem., June 16, 2006; 281(24): 16691 - 16699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, R. White, and Z. Yuan Proteomic Study of Peptide Deformylase Inhibition in Streptococcus pneumoniae and Staphylococcus aureus. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1656 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Watters, R. N. Jones, J. A. Leeds, G. Denys, H. S. Sader, and T. R. Fritsche Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004) J. Antimicrob. Chemother., May 1, 2006; 57(5): 914 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fonseca-Aten, C. M. Salvatore, A. Mejias, A. M. Rios, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken Jr, and R. D. Hardy Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4128 - 4136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Edelstein, B. Hu, and M. A. C. Edelstein In Vitro and Intracellular Activities of LBM415 (NVP PDF-713) against Legionella pneumophila Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2533 - 2535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Waites, N. B. Reddy, D. M. Crabb, and L. B. Duffy Comparative In Vitro Activities of Investigational Peptide Deformylase Inhibitor NVP LBM-415 and Other Agents against Human Mycoplasmas and Ureaplasmas Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2541 - 2542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Snydman, N. V. Jacobus, and L. A. McDermott Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group J. Antimicrob. Chemother., June 1, 2005; 55(6): 1024 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Fritsche, H. S. Sader, R. Cleeland, and R. N. Jones Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1468 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bell, J. D. Turnidge, M. Inoue, S. Kohno, Y. Hirakata, Y. Ono, and R. N. Jones Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan J. Antimicrob. Chemother., February 1, 2005; 55(2): 276 - 278. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ednie, G. Pankuch, and P. C. Appelbaum Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4027 - 4032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Credito, G. Lin, L. M. Ednie, and P. C. Appelbaum Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4033 - 4036. [Abstract] [Full Text] [PDF]
|
|